Nausea and vomiting of pregnancy. Hyperemesis gravidarum, mild or unspecified, starting before the end of the 22nd week of gestation
Conditions
Interventions
Intervention 1: Intervention group: Aromatherapy with combined lemon and peppermint essential oil, participants when feel nausea, place 3 drops of solution on the cotton, and keep it in distance of 3c
Treatment - Drugs
Placebo
Intervention group: Aromatherapy with combined lemon and peppermint essential oil, participants when feel nausea, place 3 drops of solution on the cotton, and keep it in distance of 3cm of their nose,
Control group:Aromatherapy with placebo, participants when feel nausea, place 3 drops of solution on the cotton, and keep it in distance of 3cm of their nose, and then breathe three times deeply throu
Sponsors
Vice chancellor for research, Birjand University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
16 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Pregnant women who are 16 to 40 years old, with 6 to16 weeks gestation; With literacy; With Singleton pregnancy; With mild to moderate nausea with or without vomiting (based on 3-12 PUQE-24 scores); Without any antiemetic or emetic drug use in the past 24 hours; Without tobacco use; Without psychological problems and unpleasant event during last 6 months; Pregnancy without signs of molar pregnancy and threatened abortion and pyelonephritis, thyroid dysfunction and digestive diseases and any other dis¬ease with nausea and vomiting as a symptom (vomiting according to pregnant women and physician examination); With phone number; Without olfactory disorder (according to patient). Exclusion criteria: Allergy or drug intolerance during intervention; Unwillingness to continue the study; using other drugs during the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of fatigue. Timepoint: Before and after intervention. Method of measurement: FSS questionnaire.;Severity of nausea and vomiting of pregnancy. Timepoint: Before and during intervention. Method of measurement: PUQE-24 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: After intervention. Method of measurement: Final questionnaire.;Satisfaction. Timepoint: After intervention. Method of measurement: Final questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh Safajou
Birjand University of Medical Siences
Outcome results
None listed